

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052846 A1

(51) International Patent Classification⁷: C07C 275/32,
275/42, 323/44, 275/40, 275/38, C07D 295/08, C07C
317/32, C07D 295/12, C07C 233/75, 237/40, 235/42,
A61K 31/16, A61P 13/00, 29/00

(21) International Application Number:
PCT/EP2003/013453

(22) International Filing Date:
28 November 2003 (28.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02027523.6 6 December 2002 (06.12.2002) EP

(71) Applicant (for all designated States except US): BAYER
HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TAJIMI**, Masaomi
[JP/JP]; 1-8-17, Sakuragaoka, Seika-cho, Soraku-gun, Ky-
oto 619-0232 (JP). **KOKUBO**, Toshio [JP/JP]; 3-15-18B,
Jingu, Nara-shi, Nara 631-0804 (JP). **SHIROO**, Masahiro
[JP/JP]; 1-3-17, Shikanodai-Minami, Ikoma-shi, Nara
630-0113 (JP). **TSUKIMI**, Yasuhiro [JP/JP]; 2-10-1,
Kukuchi, Amagasaki-shi, Hyogo 661-0977 (JP). **YURA**,
Takeshi [JP/JP]; 1-1-17-101, Saidaiji-Nogami-cho,
Nara-shi, Nara 631-0833 (JP). **URBAHNS**, Klaus
[DE/JP]; 6-3-1-301, Kusugaoka-cho, Nada-ku, Kobe-shi,
Hyogo 657-0024 (JP). **YAMAMOTO**, Noriyuki [JP/JP];
6-6-1-3-404, Jingu, Nara-shi, Nara 631-0804 (JP). **MOGI**,
Muneto [JP/JP]; 5-10-57-102, Daijani, Nara-shi, Nara
630-8133 (JP). **FUJISHIMA**, Hiroshi [JP/JP]; 3-23-25,

Sakyo, Nara-shi, Nara 631-0801 (JP). **MASUDA**, Tsu-
tomu [JP/JP]; 3-15-6-6A, Jingu, Nara-shi, Nara 631-0804
(JP). **YOSHIDA**, Nagahiro [JP/JP]; 5-18-15 Saganakadai,
Kizu-cho, Soraku-gun, Kyoto 619-0223 (JP). **MORI-
WAKI**, Toshiya [JP/JP]; 2-25-4, Kitayamato, Ikoma-shi,
Nara 630-0121 (JP).

(74) Common Representative: **BAYER HEALTHCARE**
AG; Low and Patents, Patents and Licensing, 51368
Leverkusen (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TETRAHYDRO-NAPHTHALENE DERIVATIVES

(57) Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

WO 2004/052846 A1